5,185 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Vise Technologies Inc.

Vise Technologies Inc. bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,185 shares of the medical research company’s stock, valued at approximately $2,102,000.

A number of other institutional investors also recently modified their holdings of TMO. Brighton Jones LLC grew its stake in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC grew its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the period. Sigma Planning Corp increased its stake in shares of Thermo Fisher Scientific by 4.4% in the 1st quarter. Sigma Planning Corp now owns 3,989 shares of the medical research company’s stock valued at $1,985,000 after acquiring an additional 169 shares in the last quarter. Cornercap Investment Counsel Inc. bought a new position in Thermo Fisher Scientific during the first quarter worth $1,499,000. Finally, Prevail Innovative Wealth Advisors LLC increased its stake in Thermo Fisher Scientific by 1,721.3% in the first quarter. Prevail Innovative Wealth Advisors LLC now owns 7,340 shares of the medical research company’s stock valued at $3,652,000 after purchasing an additional 6,937 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company increased their price objective on shares of Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. UBS Group increased their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating for the company. Finally, Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the stock an “overweight” rating in a report on Tuesday, October 28th. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $586.37 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company has a market cap of $220.30 billion, a P/E ratio of 33.87, a P/E/G ratio of 3.27 and a beta of 0.82. The firm has a 50-day moving average of $522.26 and a 200-day moving average of $465.01. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same period last year, the business posted $5.28 earnings per share. Thermo Fisher Scientific’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a stock repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 7,250 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $566.10, for a total value of $4,104,225.00. Following the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $64,400,668.20. This represents a 5.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 46,645 shares of company stock worth $25,825,699. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.